Artelo Biosciences, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. It has no approved products and generates no revenue.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $464,000 | $307,000; up $157,000 |
| General and administrative expense | $1.482 million | $1.389 million; up $93,000 |
| Total operating expenses | $1.946 million | $1.696 million; up $250,000 |
| Net loss | $1.965 million | $1.695 million |
| Basic and diluted loss per share | $0.05 | $0.09 |
| Net cash used in operating activities | $2.053 million | $1.742 million |
There is no meaningful revenue-based margin to report. The increase in R&D expense was attributed primarily to payroll and subcontractor costs for ART27.13 clinical trials. G&A rose modestly. The smaller per-share loss versus 2021 reflects a substantially higher weighted-average share count in 2022 (42.301 million versus 19.688 million), while the total net loss increased.
At March 31, 2022, cash and cash equivalents were $10.350 million and marketable securities totaled $13.161 million, for approximately $23.511 million in cash and investments. Working capital was $23.714 million; total assets were $26.704 million and total liabilities were $924,000. Liabilities included operating lease obligations; the filing reports no borrowings or other debt. Management expects existing cash and investments to fund planned operations into the second half of 2023, while anticipating operating losses and operating cash use will increase as programs advance.
Operating cash use was partly offset by $624,000 of non-cash stock-based compensation. Investing activities provided net cash of $257,000, including proceeds from securities dispositions offset by securities purchases; there were no financing cash flows in Q1 2022. Cash declined $1.812 million during the quarter. An unrealized loss on available-for-sale securities and foreign-currency translation contributed to a $46,000 other comprehensive loss.
Programs, outlook, and material risks
- ART27.13: In a Phase 1b/2a study, CAReS, for cancer-related anorexia. Management expected enrollment in the three planned Phase 1 cohorts to finish in the first half of 2022 and planned to report results after verification. A fourth cohort could be considered before dose selection for Phase 2. The filing says COVID-19 had caused minor delays.
- ART26.12: Preclinical FABP5-inhibitor program, with cancer as the current focus. Management anticipated cancer clinical studies could begin in early 2023, depending partly on enabling studies, contractors, and pandemic effects.
- ART12.11: Preclinical CBD cocrystal program. The company describes potential formulation advantages, but these remain development expectations, not demonstrated clinical outcomes.
- Management says the company will remain dependent on financing until it generates material revenue. It may need additional capital; financing may not be available on acceptable terms and could dilute shareholders or require program delays, scaling back, or licensing rights.
- Key risks include clinical-trial failure or delay, patient recruitment and supply-chain disruption, regulatory and controlled-substance requirements, dependence on third-party researchers and manufacturers, intellectual-property and license obligations, and uncertainty around future financing. COVID-19 could affect trials, supply, and costs.
- The filing reports a Nasdaq minimum-bid-price deficiency notice and a second compliance period through September 12, 2022; failure to regain compliance could lead to delisting. Management reported disclosure controls were effective and no material change in internal control over financial reporting. No material legal proceedings were reported.
Important facts for investors to verify
- Actual CAReS cohort enrollment, verified Phase 1 results, and subsequent Phase 2 dose and timing decisions.
- Whether the stated cash runway into the second half of 2023 remains achievable as operating losses and trial spending increase.
- Progress toward ART26.12 enabling studies and the projected early-2023 clinical-start timing.
- Nasdaq bid-price compliance status and any resulting financing, reverse-split, or listing actions.
- Future stock-based compensation and related-party costs: Q1 compensation expense was $624,000, of which $563,000 was attributed to related parties.